Chadwick Jeremy G 4

What Happened
Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics (KYMR), exercised stock options and sold the resulting shares in mid‑April 2026. On April 14 and 15, 2026 he exercised/options conversions totaling 6,551 shares (4,466 @ $30.17; 2,085 = 785 + 1,300 @ $43.50), costing $225,437 in aggregate, and sold those 6,551 shares in open‑market transactions at roughly $90.00 (weighted average), generating gross proceeds of about $589,598.

Key Details

• Transaction dates: April 14, 2026 and April 15, 2026; Form filed April 16, 2026 (timely filing).
• Exercise specifics: 4,466 shares @ $30.17 = $134,739; 785 shares @ $43.50 = $34,148; 1,300 shares @ $43.50 = $56,550.
• Sales: 5,251 shares sold on April 14 for $472,598 (weighted avg $90.00); 1,300 shares sold on April 15 for $117,000 (sales prices ranged $90.00–$90.10 per footnote). Total proceeds ≈ $589,598.
• Footnotes: Transactions were effected pursuant to a Rule 10b5‑1 trading plan dated Dec 10, 2025 (F1). Sales price is a weighted average; individual trades ranged $90.00–$90.10 (F2). Two option grants have 36‑month monthly vesting schedules starting Mar 3, 2025 and Mar 1, 2024 (F3, F4).
• Derivative reporting: The filing shows the options were exercised (acquired shares) and the derivative interests were converted/removed (reported as disposed at $0) upon exercise.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context
This was an exercise of options followed by immediate open‑market sales, executed under a preplanned 10b5‑1 program. Such executions are commonly used to automate sales and reduce the appearance of opportunistic timing; they are routine for executives exercising vested (or vesting) options. The filing is informational and does not, by itself, indicate the insider’s view on the company’s prospects.